Virobay
2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more
2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more
2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more
2010 – Virobay closes Series B financing
2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I
2007 – In-licensed cathepsin protease inhibitor assets
2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C
2006 – Founded as a protease inhibitor drug discovery and development company
